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spontaneously after 2 to 3 days. No other adverse events were
observed during eltrombopag treatment or at the follow-up visits rou-
tinely performed 30 days after surgery. As eltrombopag has been asso-
ciated with occurrence of cataracts in patients with immune
thrombocytopenia, and MYH9-RD is a syndromic disorder predisposing
to cataracts,2,3 ophthalmological evaluation was carried out at every
follow-up visit. None of our patients showed occurrence or worsening
of cataracts, not even patients 1 to 3 who already presented cataracts
at baseline and received repeated eltrombopag courses.
In summary, eltrombopag successfully replaced platelet transfusions
in preparation for surgery in 10 of 11 cases. Importantly, this drug pro-
vided a simple and safe option for increasing platelet count in case of
refractoriness to platelet transfusions. Another advantage of eltrombo-
pag compared to prophylactic platelet transfusions is that the drug
induced a stable increase of platelet count throughout the perioperative
period, thus also allowing the safe administration of a standard antith-
rombotic prophylaxis, and, in some cases, avoiding hospitalization. In
our real-life setting, short-term eltrombopag was safe with no signifi-
cant adverse events reported. However, since thrombopoietin-
mimetics have been associated with potentially severe adverse events
in acquired thrombocytopenias, including thrombosis, the risk-benefit
ratio of eltrombopag administration should be always carefully assessed
for each MYH9-RD patient. In conclusion, our data suggest that short-
term eltrombopag should be considered as the first-line treatment to
prepare MYH9-RD patients with severe thrombocytopenia for elective
surgery.
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BMI is an important
determinant of VWF and FVIII
levels and bleeding phenotype
in patients with von
Willebrand disease
To the Editor:
In the general population, it has been shown that higher body-mass index
(BMI) is associated with increased von willebrand factor (VWF) and factor
VIII (FVIII) levels.1 A higher BMI is also associated with other procoagulant
hemostatic changes, and may therefore protect against bleeding.1 The
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association between BMI, VWF and FVIII levels, and bleeding phenotype
is unknown in von Willebrand disease (VWD) patients. We hypothesize
that higher BMI increases VWF and FVIII levels in patients with VWD,
and thereby may ameliorate the bleeding phenotype. Therefore, we
investigated the association between BMI, VWF and FVIII levels, and the
bleeding phenotype in a large cohort of type 1 and type 2 VWD patients.
We included patients from a nationwide cross-sectional study in VWD
patients in the Netherlands, known as the “Willebrand in the Netherlands
Study” (WiN study).2,3 The inclusion criteria were hemorrhagic symptoms
or a family history of VWD, and historically lowest VWF:Ag and/or VWF:
RCo ≤0.30 IU/mL and/or FVIII levels (FVIII:C) ≤0.40 IU/mL (for type 2N
VWD). For this study, we excluded patients with type 3 VWD (VWF levels
and VWF propeptide [VWFpp] <0.05 IU/mL), because these patients have
by definition undetectable VWF levels. We categorize type 1 and type
2VWDbased on aVWF:Ab/VWF:Ag ratio of above and below0.60.4
Furthermore,we excludedpatients younger than16 years old, because
BMI reference ranges are different in children of a young age compared to
adults. Blood samples were obtained at study inclusion. All patients signed
informed consent. The assessmentmethods, blood sampling procedure, and
laboratory measurements have been described in detail previously.2,3
Briefly, patients filled inaquestionnaireoncomorbidities, a self-administered
version of the condensedTosetto bleeding score andbleeding episodes that
required hemostatic treatment in the year prior to inclusion. BMIwas calcu-
lated with the formula weight (kg)/height (m) × height (m). BMI was catego-
rized in four groups of underweight (BMI: <18.5 kg/m2), normal weight
(18.5-25 kg/m2), overweight (25-30 kg/m2), andobesity (≥30 kg/m2).
We compared continuous variables between two groups using an
independent t test, and categorical variables with a chi-square test.
The association between BMI categories and occurrence of bleeding
in the year prior to inclusion in the study was adjusted for confounders
using logistic regression analysis. Outcomes of logistic regression analysis
are reported as odds ratio and 95% confidence interval (CI). Multiple
regression analyses were used to analyze the association between BMI
and VWF and FVIII levels and total bleeding score. We report linear
regression outcomes as unstandardized β coefficient (difference) and
95%CI. In the logistic and multiple regression analysis, confounders were
selected based on previous literature (age, sex, blood group [O vs non-O],
and presence of relevant comorbidities [cancer, hypertension, diabetes,
and thyroid gland dysfunction]).3 Statistical analyses were performed with
SPSS Statistics version 24 (IBM Corp., Armonk, New York).
From the total WiN study population aging 16 years and older
(n = 688), 94 patients without centrally measured VWF and FVIII levels,
14 patients with type 3 VWD and 35 patients with missing data on
length or weight were excluded. We included 545 VWD patients of
whom 349 patients had type 1 and 196 patients had type 2 VWD.
Table 1 shows the patient characteristics. The mean BMI was
25.4  4.3 kg/m2. The mean age was 46  15 years. There was no
difference in BMI between patients with type 1 and type 2 VWD
(25.5  4.4 vs 25.2  4.3, P = .550, Table 1).
Among patients with type 1 VWD, higher BMI was associated
with higher VWF:Ag, VWF:CB, VWF:Ab and FVIII:C, respectively
0.07 IU/mL (0.02-0.13), 0.07 IU/mL (0.00-0.14), 0.09 IU/mL (0.01-0.17),
and 0.13 IU/mL (0.05-0.21) per 10 kg/m2 increase in BMI (adjusted for
age, sex, blood group, and presence of relevant comorbidities). In type
2 VWD, VWF:Ag and FVIII:C were associated with higher BMI, respec-
tively 0.04 IU/mL (−0.02-0.10) and 0.09 IU/mL (0.00-0.17) per 10 kg/m2
increase in BMI (adjusted for age, sex, blood group, and presence of rele-
vant comorbidities). Similarly, in type 1 VWD, a linear association was
observed between BMI categories (underweight, normal weight, over-
weight, and obesity) and VWF levels (Figure 1A), whereas in type 2 VWD,
there was a linear association between BMI categories and VWF:Ag and
FVIII:C (Figure 1B).
In the total VWD population, patients with normal weight had
fewer bleeding episodes requiring hemostatic treatment in the year
TABLE 1 Patient characteristics
Type 1 VWD
n = 349
Type 2 VWD
n = 196
Total patients
n = 545
Age, mean  SD 46  15 46  16 46  15
Female, n (%) 244 (70%)* 109 (56%)* 353 (65%)
Blood group O, n (%) 241 (69%)* 97* (50%)* 338 (62%)
BMI, mean  SD 25.5  4.4 25.2  4.3 25.4  4.3
VWF:Ag 0.37 [0.23-0.53]* 0.26 [0.17-0.36]* 0.31 [0.19-0.47]
VWF:CB 0.42 [0.23-0.66]* 0.08 [0.06-0.14]* 0.26 [0.09-0.54]
VWF:Ab 0.45 [0.23-0.70]* 0.08 [0.03-0.17]* 0.25 [0.11-0.56]
FVIII:C 0.66 [0.49-0.87]* 0.38 [0.28-0.49]* 0.54 [0.36-0.77]
Bleeding score 9 [5-15]* 12 [8-17]* 11 [6-16]
Number of patients with bleeding in the year prior to inclusion per BMI category
<18.5 kg/m2 4/9 (44%) 1/4 (25%) 5/13 (39%)
18.5-25 kg/m2 28/170 (17%) 41/106 (39%) 69/276 (25%)
25-30 kg/m2 30/116 (26%) 23/59 (39%) 53/175 (30%)
≥30 kg/m2 16/54 (30%)** 15/27 (56%) 31/81 (38%)**
Note: Data are presented as median [interquartile ranges], unless otherwise specified.
Abbreviations: BMI, body-mass index (kg/m2); SD, standard deviation; VWD, von Willebrand disease.
*P value below 0.05 between patients with type 1 and type 2 VWD.
**P value below 0.05 compared to BMI category 18.5-25 kg/m2.
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prior to inclusion in the study than patients with overweight and
obesity, respectively 25% (69/276) vs 30% (53/175) and 38%
(31/81) (P = .018, Table 1). In type 1 VWD, the proportion of
patients with bleeding was almost two times higher in patients with
obesity compared to patients with normal weight (relative risk 1.8,
30% (16/54) vs 17% (28/170), P = .034, Table 1). After adjustment
for age, sex, blood group, and presence of relevant comorbidities,
the odds ratio was 1.91 (0.89-4.11). In type 2 VWD, a higher propor-
tion of patients with obesity tended to have a bleeding episode
requiring hemostatic treatment in the year prior to inclusion than
patients with normal weight (relative risk 1.4, 56% (15/27) vs 39%
(41/106), P = .113, Table 1). In type 1 and type 2 VWD patients
there was no clear association between BMI and the total (life time)
bleeding score, respectively 0.54 (−1.16-2.25) and 1.35 (−0.94-3.63)
per 10 kg/m2 increase in BMI.
In this study we demonstrate that BMI is an important determi-
nant of VWF and FVIII levels in patients with VWD. Although in the
general population an association between BMI and VWF and FVIII
levels was observed previously, this association is demonstrated in
this study for the first time in patients with VWD. In accordance, it
has previously been suggested that most VWF expression is seen in
adipose-subcutaneous tissue, and therefore individuals with more
adipose-subcutaneous tissue (ie, higher BMI) have higher VWF expres-
sion, leading to higher VWF and FVIII levels.5
Despite an association with higher VWF and FVIII levels, BMI
does not seem to protect against bleeding. VWD patients with obesity
and overweight experienced even more bleeding symptoms in the
year prior to the study than VWD patients with normal weight. This
suggests that overweight and obese VWD patients, who have slightly
higher VWF levels compared to VWD patients with a normal weight,
are not protected against bleeding and still need to receive prophylac-
tic treatment during interventions. Furthermore, our results indicate
that the increase in VWF and FVIII levels in overweight and obese
patients is insufficient to prevent bleeding, and that other determi-
nants than VWF and FVIII levels influence the bleeding tendency of
these patients6 more frequent surgical treatment, because overweight
and obese patients may need more often surgery due to BMI associ-
ated comorbidities, such as orthopedic problems, and therefore have a
higher risk of bleeding. Additionally, factors outside the hemostatic sys-
tem, such as vascular damage, more frequent falls and poor wound
healing could potentially have a role in the bleeding tendency of these
patients.6 This is supported by several large studies in the past that
found that obesity, despite causing procoagulant hemostatic changes,
does not protect against bleeding.6
This is the first study to demonstrate an important association
between BMI, VWF and FVIII levels, and bleeding phenotype in VWD
patients. The main limitation of this study is that we did not have lon-
gitudinal VWF measurements in patients over time. However, BMI
remains quite constant with aging, and therefore intra-individual anal-
ysis would probably be less informative than inter-individual analysis,
which was performed in this study.
To conclude, higher BMI is associated with higher VWF and FVIII
levels in patients with type 1 and type 2 VWD. However, higher BMI
does not seem to protect against bleeding. Despite higher VWF and
FVIII levels, VWD patients with overweight and obesity had more
bleeding symptoms in the year prior to inclusion than patients with
normal weight.
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Disparities in the risk of septic
events in patients undergoing
splenectomy for
hematological malignancies
(D-ROSE-PUSH): A study
based on ACS-NSQIP
database
To the Editor:
Studies evaluating nontraumatic splenectomy in patients with myeloid
and lymphoid malignancies reported particularly higher morbidity and
mortality rates, ranging between 24%-52% and 2%-18%
respectively.1–4 Infectious complications including sepsis have been
reported to be significantly more common in patients with malignant
indications for splenectomy.5 The goal of this analysis was to evaluate
the risk of postoperative septic events in patients undergoing splenec-
tomy for lymphoid and myeloid malignancies as compared to patients
with nonmalignant, benign indications.
Our study was a retrospective cohort study of the prospective
validated American College of Surgeons National Surgical Quality
Improvement Program (ACS-NSQIP) database from 2008 to 2016.
Cases with the Current Procedural Terminology (CPT) codes 38100
and 38120 were included. These CPT codes included all the cases of
total splenectomy, laparoscopic, and open that were not performed
as add-on procedures. Cases with CPT codes 38101 (partial splenec-
tomy) and 38102 (splenectomy as add-on procedure) were not
included in the analysis. Only the index case was included for
patients undergoing more than one procedure. Patients were not
included more than once in the analysis.
The patient population was subsequently stratified based on
whether the postoperative diagnosis was part of the preidentified
group of “malignant lymphoid and myeloid neoplasms/leukemia.”
This group of diseases included the following International Classifi-
cation of Disease Ninth Edition (ICD-9) diagnoses (200.X-208.X) and
International Classification of Disease Tenth Edition (ICD-10) diag-
noses (C81.X-C96.X). This group of diagnoses includes lymphosar-
coma, Hodgkin's disease, other malignant neoplasms of lymphoid
and histiocytic tissue, multiple myeloma, immunoproliferative neo-
plasms, lymphoid leukemia, myeloid leukemia, monocytic leukemia,
and other leukemic diseases.
The primary outcome measure was the incidence of postoperative
septic events, including sepsis and septic shock, at 30 days of the index
surgery in the group with lymphoid and myeloid malignancy (neoplasms
or leukemia as previously defined) compared with the group without
lymphoid or myeloid malignancy. Per ACS-NSQIP sepsis was considered
present when a subject had evidence of systemic inflammatory response
with either (i) positive blood culture (or clinical documentation of puru-
lence or positive culture from any site for which there is documentation
noting the site as the acute cause sepsis) or (ii) suspected preoperative
clinical condition of infection or bowel infarction leading to the surgical
procedure. Septic shock was defined as sepsis with documented organ
and/or circulatory dysfunction. Both sepsis and septic shock were con-
sidered septic events. A multivariate logistic regression model for post-
operative septic events at 30 days was created with adjusted odds
ratios (ORadj). Clinically relevant potential confounders in each separate
model were considered for adjustments. Stepwise regression was per-
formed with an entry level of 0.25 and a stay level of 0.15. The associa-
tion was further evaluated across strata of age, sex, and emergency
status. The interaction was assessed for the 30-day septic events out-
come. All P values were two-sided with level of significance <0.05. Sta-
tistical analysis was done using Statistical Analysis System. In compliance
with the guidelines of the American University of Beirut Institutional
Review Board, ethical review was not needed for our analysis.
A total of 7721 patients met the inclusion criteria and were
included in the analysis. The mean age of the patients was 54.0 years
(SD 17.69 years). 52.5% of patients were female. 4081 (52.9%) of the
procedures were done laparoscopically. Baseline characteristics are
reported in Table S1. There was no statistically significant difference in
postoperative septic events between the patients who underwent sple-
nectomy for lymphoid malignancy vs those who underwent splenec-
tomy for other indications without adjusting for other factors.
Unadjusted risk for 30-day postoperative septic events was not statisti-
cally significantly different (ORunadjusted = 1.16 with a 95% CI of
0.85-1.57) between patients with lymphoid or myeloid malignancy and
patients with benign indications for splenectomy. Table 1 shows the
non-stratified and stratified results on 30-day postoperative septic
events across the different groups. For patients with lymphoid or mye-
loid malignancy undergoing splenectomy, the adjusted OR for postop-
erative septic events was 1.20 (95% confidence interval of 0.87-1.66)
as compared to patients with other postoperative diagnoses. Based on
the adjusted OR, patients with myeloid and lymphoid neoplasms were
not at a higher risk of postoperative septic events. When the sub-
groups were stratified by age, sex, and emergency status, females
undergoing splenectomy for a malignant indication were at a statisti-
cally significantly increased risk of postoperative septic events with
ORadjusted = 1.83 (95% confidence interval of 1.12-2.99) when com-
pared with females undergoing splenectomy for other indications.
In our analysis, the preoperative risk factors found to be associated
with postoperative septic events included older age, age 65 years or
older, male sex, functional dependence, and inpatient hospitalization sta-
tus. Having a higher American Society of Anesthesiologists class was
associated with higher risk for postoperative septic events. The use of
general anesthesia did not affect the risk of postoperative septic events.
Emergency cases were associated with twofold increased risk of postop-
erative septic events. Perioperative transfusion, longer operative time,
and open approach (vs laparoscopic) were associated with increased risk
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